| 何丽亚,吴政治,王平,等.miR-29b在2型糖尿病和前期糖尿病患者血清中的表达及临床意义[J].安徽医药,2018,22(7):1331-1334. |
| miR-29b在2型糖尿病和前期糖尿病患者血清中的表达及临床意义 |
| Expression and clinical significance of serum miR-29b in type 2 diabetes mellitus and pre-diabetes |
| 投稿时间：2017-02-21 |
| DOI： |
| 中文关键词: 糖尿病, 2型 葡糖耐量试验 人体质量指数 高血压 分子诊断技术 微小RNA 29b |
| 英文关键词: Diabetes mellitus, type 2 Glucose tolerance test Body mass index Hypertension Molecular diagnostic techniques MiR-29b |
| 基金项目: |
|
| 摘要点击次数: 2029 |
| 全文下载次数: 595 |
| 中文摘要: |
| 目的 探讨血清miR-29b作为生物标志物在2型糖尿病(T2D)和前期糖尿病中的诊断价值。方法 应用RT-PCR检测24例T2D患者、22例空腹血糖受损(IFG)或葡萄糖耐量受损(IGT)的前期糖尿病患者以及24例健康对照者的血清中miR-29b的表达水平,并通过多因素logistic回归和受试者工作特征(ROC)分析明确miR-29b潜在的诊断价值。结果 与健康对照组(1.03±0.38)相比,T2D(0.49±0.24)和IFG/IGT(0.50±0.33)患者的血清miR-29b表达水平显著降低(P<0.05)。多因素logistic回归分析证实低表达miR-29b与T2D(OR:0.51; 95％CI:0.16～0.73; P<0.05)和IFG/IGT(OR:0.56; 95％CI:0.23～0.79; P<0.05)明显相关。这种关联在考虑年龄、BMI指数和高血压以及其他生化指标后仍然差异有统计学意义。此外,ROC分析显示,血清miR-29b能清楚区分健康对照和T2D(AUC 0.864; 95％CI 0.759～0.969; P<0.001)、IFG/IGT(AUC 0.846; 95％CI 0.737～0.954; P<0.001)患者。结论 T2D和IFG/IGT患者血清miR-29b表达水平显著降低,可以作为T2D和IFG/IGT潜在的诊断指标。 |
| 英文摘要: |
| Objective To investigate the diagnostic value of serum miR-29b as a biomarker in type 2 diabetes (T2D)and pre-diabetes. Methods The expression levels of serum miR-29b of 24 patients with T2D, 22 patients with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) and 24 healthy controls were measured by RT-PCR. Multivariate logistic regression and receiver operating characteristic (ROC) analysis were conducted to evaluate potential diagnostic value of miR-29b. Results Serum miR-29b expression levels were significantly decreased in patients with T2D and IFG/IGT individuals, compared with healthy control subjects (P<0.05). As determined by multivariate logistic regression analysis, lower miR-15a expression was significantly associated with T2D (OR:0.51; 95％CI:0.16-0.73; P<0.05) and IFG/IGT (OR, 0.56; 95% CI, 0.23~0.79; P<0.05). This association remained statistically significant following adjustment for age, body mass index and hypertension, as well as other biochemical indicators. Furthermore, ROC analysis revealed that blood miR-29b distinguished patients with T2D and IFG/IGT individuals from healthy controls (AUC 0.864; 95％CI 0.759-0.969; P<0.001 and AUC 0.846; 95％CI 0.737-0.954; P<0.001, respectively). Conclusion Serum miR-29b expression levels are significantly lower in patients with T2D and IFG/IGT individuals, and miR-29b in serum may serve as a potential biomarker for T2D and IFG/IGT diagnosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
